Literature DB >> 27924615

A Model for Predicting the Interindividual Variability of Drug-Drug Interactions.

M Tod1,2,3, L Bourguignon4,5,6, N Bleyzac7,8, S Goutelle4,5,6.   

Abstract

Pharmacokinetic drug-drug interactions are frequently characterized and quantified by an AUC ratio (Rauc). The typical value of the AUC ratio in case of cytochrome-mediated interactions may be predicted by several approaches, based on in vitro or in vivo data. Prediction of the interindividual variability of Rauc would help to anticipate more completely the consequences of a drug-drug interaction. We propose and evaluate a simple approach for predicting the standard deviation (sd) of Ln(Rauc), a metric close to the interindividual coefficient of variation of Rauc. First, a model was derived to link sd(Ln Rauc) with the substrate fraction metabolized by each cytochrome and the potency of the interactors, in case of induction or inhibition. Second, the parameters involved in these equations were estimated by a Bayesian hierarchical model, using the data from 56 interaction studies retrieved from the literature. Third, the model was evaluated by several metrics based on the fold prediction error (PE) of sd(Ln Rauc). The median PE was 0.998 (the ideal value is 1) and the interquartile range was 0.96-1.03. The PE was in the acceptable interval (0.5 to 2) in 52 cases out of 56. Fourth, a surface plot of sd(Ln Rauc) as a function of the characteristics of the substrate and the interactor has been built. The minimal value of sd(Ln Rauc) was about 0.08 (obtained for Rauc = 1) while the maximal value, 0.7, was obtained for interactions involving highly metabolized substrates with strong interactors.

Entities:  

Keywords:  cytochromes; drug interactions; interindividual variability; pharmacokinetics; prediction model

Mesh:

Substances:

Year:  2016        PMID: 27924615     DOI: 10.1208/s12248-016-0021-0

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  65 in total

1.  Effect of rifampin on plasma concentrations of mefloquine in healthy volunteers.

Authors:  W Ridtitid; M Wongnawa; W Mahatthanatrakul; P Chaipol; M Sunbhanich
Journal:  J Pharm Pharmacol       Date:  2000-10       Impact factor: 3.765

Review 2.  Controversies in bioequivalence studies.

Authors:  V W Steinijans; D Hauschke; J H Jonkman
Journal:  Clin Pharmacokinet       Date:  1992-04       Impact factor: 6.447

3.  Blood concentrations of everolimus are markedly increased by ketoconazole.

Authors:  J M Kovarik; D Beyer; M N Bizot; Q Jiang; M Shenouda; R L Schmouder
Journal:  J Clin Pharmacol       Date:  2005-05       Impact factor: 3.126

4.  Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride.

Authors:  M Niemi; K T Kivistö; J T Backman; P J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  2000-12       Impact factor: 4.335

5.  Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.

Authors:  A L Mazzu; K C Lasseter; E C Shamblen; V Agarwal; J Lettieri; P Sundaresen
Journal:  Clin Pharmacol Ther       Date:  2000-10       Impact factor: 6.875

6.  General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information.

Authors:  Yoshiyuki Ohno; Akihiro Hisaka; Masaki Ueno; Hiroshi Suzuki
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

7.  Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole.

Authors:  Robert Z Harris; Margaret Salfi; John T Sullivan; Desmond Padhi
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

8.  Effect of omeprazole on the steady-state pharmacokinetics of voriconazole.

Authors:  Nolan Wood; Keith Tan; Lynn Purkins; Gary Layton; Julia Hamlin; Diane Kleinermans; Don Nichols
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

9.  Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone.

Authors:  T S Lamberg; K T Kivistö; P J Neuvonen
Journal:  Clin Pharmacol Ther       Date:  1998-06       Impact factor: 6.875

10.  Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole.

Authors:  Paul Martin; Stuart Oliver; Jane Robertson; Sarah-Jane Kennedy; Jessica Read; Thierry Duvauchelle
Journal:  Drugs R D       Date:  2011
View more
  4 in total

1.  A Generic Model for Quantitative Prediction of Interactions Mediated by Efflux Transporters and Cytochromes: Application to P-Glycoprotein and Cytochrome 3A4.

Authors:  Michel Tod; S Goutelle; N Bleyzac; L Bourguignon
Journal:  Clin Pharmacokinet       Date:  2019-04       Impact factor: 6.447

2.  Identification of Cytochrome P450-Mediated Drug-Drug Interactions at Risk in Cases of Gene Polymorphisms by Using a Quantitative Prediction Model.

Authors:  Nicolas Fermier; Laurent Bourguignon; Sylvain Goutelle; Nathalie Bleyzac; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

3.  Quantitative Prediction of Interactions Mediated by Transporters and Cytochromes: Application to Organic Anion Transporting Polypeptides, Breast Cancer Resistance Protein and Cytochrome 2C8.

Authors:  Michel Tod; Laurent Bourguignon; Nathalie Bleyzac; Sylvain Goutelle
Journal:  Clin Pharmacokinet       Date:  2020-06       Impact factor: 6.447

4.  Does DDI-Predictor Help Pharmacists to Detect Drug-Drug Interactions and Resolve Medication Issues More Effectively?

Authors:  Fanny Moreau; Nicolas Simon; Julia Walther; Mathilde Dambrine; Gaetan Kosmalski; Stéphanie Genay; Maxime Perez; Dominique Lecoutre; Stéphanie Belaiche; Chloé Rousselière; Michel Tod; Bertrand Décaudin; Pascal Odou
Journal:  Metabolites       Date:  2021-03-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.